- (PLX AI) – Bayer says U.S. FDA approves expansion of the peripheral artery disease (PAD) indication for Xarelto plus aspirin.
- • Patients after recent lower-extremity revascularization due to symptomatic PAD now included in the label in the US
- • Xarelto plus aspirin is the first treatment approach indicated in the US for both coronary artery disease (CAD) and PAD, now including patients post recent lower-extremity revascularization (LER) due to symptomatic PAD, Bayer says
- • Xarelto is the only anticoagulant in more than 20 years to show a significant benefit in patients with PAD who remain at high risk for major thrombotic events post lower extremity revascularization, Bayer says